含莫西沙星三联疗法在老年幽门螺杆菌感染补救治疗中的疗效观察

目的观察含莫西沙星的三联疗法治疗老年初治失败的幽门螺杆菌（Hpylori）感染的临床疗效及不良反应。方法将94例经标准三联疗法治疗失败的Hpylori感染老年患者随机分成A组和B组，每组47例。A组给予口服雷贝拉唑20mg（2次／d）＋阿莫西林1g（2次／d）＋莫西沙星400mg（1次／d）；B组给予口服雷贝拉唑20mg（2次，d）＋枸橼酸铋钾300mg（4次／d）＋呋喃唑酮100mg（2次／d）＋阿莫两林ig（2次／d）。两组均治疗7d，治疗结束后4W进行”C尿素呼气检测试验。结果A、B两组的根除率（ITT）分别为91．5％和72．3％（P〈0．05）；不良反应发生率分别为8．5％和27．6％（P〈0．05）。结论莫西沙星三联疗法治疗仞治失败的老年幽门螺杆菌感染是一种有效，安全的治疗方案。

The efficacy of moxifloxacin based triple therapy on treatment of the elderly patients with Helicobacter pylori infection eradication failure

Objective To investigate the efficacy and tolerablity of moxifloxacin based triple therapy on eradication of helicobacter pylori （H. pylori ） infection after first treatment failure in the elderly patients. Methods 94 patients, who was failed to eradicate H. pylori by standard triple therapy, were randomized to receive the 7-day oral regimens： Group A （n=47）, rabeprazole 20 mg bid, amoxicillin 1 g bid, and moxifloxacin 400 mg qd; while Group B （n=47）, rabeprazole. 20 mg bid, amoxicillin 1 g bid, bismuth potassium citrate 300 mg qid, and furazolidone 0.1 bid. H. pylori status was reassessed with the 13C-urea breath test four weeks later after treatment. Results The rates ofH. pylorieradication in groups A and B were 91.5% and 72.3%, respectively （P〈0.05）. The occurrences of total side effects in group A and B were 8.5% and 27.6% （P〈0.05）. Conclusion The moxifloxacin based triple therapy is an effective, safe regimen after the eradication failure of H. pylori infection in elderly patients.